Skip to main content

Table 2 Tumor response

From: Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination

 

TACE plus apatinib plus camrelizumab (n = 80)

Best overall response

 Complete response (CR)

14 (17.5)

 Partial response (PR)

33 (41.3)

 Stable disease (SD)

18 (22.5)

 Progressive disease (PD)

15 (18.7)

ORR (CR + PR)

47 (58.8, 47.2–69.6)

DCR (CR + PR + SD)

65 (81.2, 71.0–89.1)

  1. Data are N (%)
  2. DCR disease control rate, ORR objective response rate, TACE transarterial chemoembolization